Novo Nordisk sues Eli Lilly over GLP-1 drug advertising

Novo Nordisk is suing Eli Lilly, claiming Lilly's GLP-1 obesity and diabetes drug advertisements use "outdated clinical trials" to make its drugs look more effective. This is an official complaint about potentially misleading consumer information from one pharma giant to another. Eli Lilly states they are confident in their advertising's compliance.